4-sec.Butylchinolin | 31688-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-sec.Butylchinolin
• 英文别名: 4-sec-butyl-quinoline；4-(1-Methylpropyl)quinoline；4-butan-2-ylquinoline
• CAS: 31688-63-8
• 化学式: C₁₃H₁₅N
• mdl: MFCD00672176
• 分子量: 185.269
• InChiKey: WGWVEBIPUZRCJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN USING THE COMPOSITION
  申请人：Takahashi Hidenori

  公开号：US20120156618A1

  公开（公告）日：2012-06-21

  According to one embodiment, an actinic-ray- or radiation-sensitive resin composition includes a resin (P) containing not only at least one repeating unit (A) that when exposed to actinic rays or radiation, is decomposed to thereby generate an acid and is expressed by any of general formulae (I) to (III) below but also a repeating unit (B) containing at least an aromatic ring group provided that the repeating unit (B) does not include any of those of general formulae (I) to (III). (The characters used in general formulae (I) to (III) have the meanings mentioned in the description.)

  根据一种实施例，一种感光射线或辐射敏感的树脂组合物包括树脂（P），该树脂不仅包含至少一个重复单元（A），当暴露于感光射线或辐射时，分解从而产生酸，并由下列任一通式（I）至（III）表示，而且还包括一个重复单元（B），其中至少包含一个芳香环基团，前提是重复单元（B）不包括通式（I）至（III）中的任何一个。（通式（I）至（III）中使用的字符在描述中有所提及。）
• IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：EP0975602A1

  公开（公告）日：2000-02-02
• EP0975602A4
  申请人：——

  公开号：EP0975602A4

  公开（公告）日：2003-01-22
• DIAZAINDOLE COMPOUNDS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3728264B1

  公开（公告）日：2021-12-01
• BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS
  申请人：Bradner James Elliot

  公开号：US20090312363A1

  公开（公告）日：2009-12-17

  In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.